Michael H. Goldstein
President chez Aurion Biotech, Inc.
Profil
Michael H.
Goldstein is currently the Co-Director of Cornea & External Disease at New England Eye Center, Director at Aramis Biosciences, Inc., and President & Chief Medical Officer at Aurion Biotech, Inc. He previously worked as the Director at Inanovate, Inc., Director of Refractive Surgery Service at the University of Florida College of Medicine, Chief Medical Officer at Ocular Therapeutix, Inc., Chief Medical Officer at Beacon Therapeutics (USA), Inc., and Chief Medical Officer & VP-Clinical Research at Sesen Bio, Inc. He also worked as an Assistant Professor of Ophthalmology at Tufts University School of Medicine.
Goldstein received his undergraduate degree from Williams College, his MBA from Kellogg School of Management, and his doctorate from Feinberg School of Medicine.
Postes actifs de Michael H. Goldstein
| Sociétés | Poste | Début |
|---|---|---|
New England Eye Center
 New England Eye Center Medical/Nursing ServicesHealth Services New England Eye Center offers a full range of ophthalmology services. It specializes in cornea, external disease, and cataracts; glaucoma; oculoplastics; pediatric ophthalmology; retinal and macular diseases; vision rehabilitation; uveitis and immunology; pediatric optometry; and vision correction surgery. The company is headquartered in Boston, MA. | Corporate Officer/Principal | 01/01/2002 |
Aramis Biosciences, Inc.
 Aramis Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals. | Director/Board Member | - |
Aurion Biotech, Inc.
 Aurion Biotech, Inc. Medical/Nursing ServicesHealth Services Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021. | President | 09/06/2022 |
Anciens postes connus de Michael H. Goldstein
| Sociétés | Poste | Fin |
|---|---|---|
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Chief Tech/Sci/R&D Officer | 05/09/2017 |
| CARISMA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/09/2016 |
| University of Florida College of Medicine | Corporate Officer/Principal | 01/12/2001 |
| Tufts University School of Medicine | Corporate Officer/Principal | - |
| OCULAR THERAPEUTIX, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Michael H. Goldstein
| Williams College | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
| Feinberg School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| OCULAR THERAPEUTIX, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Inanovate, Inc.
 Inanovate, Inc. Information Technology ServicesTechnology Services Inanovate, Inc. provides protein screening services. Its product include Bio-ID, a multiplexed protein quantification platform which, in real-time, measures protein concentrations from matrices. The company was founded by David Alexander Ure and David J Arslanian in 2007 and is headquartered in Sioux Falls, SD. | Technology Services |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
New England Eye Center
New England Eye Center Medical/Nursing ServicesHealth Services New England Eye Center offers a full range of ophthalmology services. It specializes in cornea, external disease, and cataracts; glaucoma; oculoplastics; pediatric ophthalmology; retinal and macular diseases; vision rehabilitation; uveitis and immunology; pediatric optometry; and vision correction surgery. The company is headquartered in Boston, MA. | Health Services |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Aramis Biosciences, Inc.
Aramis Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals. | Health Technology |
Aurion Biotech, Inc.
Aurion Biotech, Inc. Medical/Nursing ServicesHealth Services Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021. | Health Services |
